Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03290547 · ClinicalTrials.gov registry record · NA
Pilot Study of Multi-wavelength Laser for Tattoo Removal
A NA study of Tattoo Removal, sponsored by Cutera.
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
- 2
- Study locations
NCT03290547: Completed NA study of Tattoo Removal, sponsored by Cutera.
NCT03290547 is a NA study of Tattoo Removal that has completed, run by Cutera. The registered enrollment target is 22 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03290547, a NA study of Tattoo Removal, has completed, sponsored by Cutera.
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
- 2
- Study locations
Study Summary
To evaluate the safety and efficacy of an investigational version of the Cutera enLighten laser that offers muliple wavelengths for tattoo removal.
Primary Outcome
Degree of tattoo clearing using the GAIS (Global Assessment of Improvement Scale) 3 = Very Significant Improvement, 2 = Significant Improvement, 1 = Moderate Improvement, or 0 = Mild or No Improvement Higher scores indicate better outcomes
Conditions Studied
Interventions
- DEVICE Cutera enLighten laser
Study Locations (2)
California
- Cutera Research Center - Brisbane
Massachusetts
- Skin Care Physicians - Chestnut Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2015-07-08 |
| Est. Completion | 2017-11-29 |
| Phase | NA |
What the finished NCT03290547 record still lists
NCT03290547 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Tattoo Removal appearing as the primary indexed condition, and to 1 intervention - of which Cutera enLighten laser is the first listed.
NCT03290547 reports a single indexed study location in California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03290547 about?
NCT03290547 is a clinical study titled "Pilot Study of Multi-wavelength Laser for Tattoo Removal". To evaluate the safety and efficacy of an investigational version of the Cutera enLighten laser that offers muliple wavelengths for tattoo removal.
What is the current status of trial NCT03290547?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2015-07-08. Estimated completion is 2017-11-29.
What conditions does trial NCT03290547 study?
This clinical trial studies the following conditions: Tattoo Removal.
What interventions are being tested in trial NCT03290547?
The interventions under investigation include: Cutera enLighten laser (DEVICE).
Who is sponsoring clinical trial NCT03290547?
This trial is sponsored by Cutera, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03290547 being conducted?
This trial has 2 study locations across California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tattoo Removal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03290547's enrollment target sits among peer trials
22 1756th of 2000 higher than 239 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI